Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Khoja,Leila; Atenafu,Eshetu G.; Ye,Qian; Gedye,Craig; Chappell,Maryanne; Hogg,David; Butler,Marcus   O.; Joshua,Anthony   M.

doi:10.3892/ol.2015.4069

February-2016 Volume 11 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2016 Volume 11 Issue 2

Full Size Image

Article

Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Authors:
- Leila Khoja
- Eshetu G. Atenafu
- Qian Ye
- Craig Gedye
- Maryanne Chappell
- David Hogg
- Marcus O. Butler
- Anthony M. Joshua
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada
Pages: 1581-1585
|
Published online on: December 31, 2015

https://doi.org/10.3892/ol.2015.4069
Expand metrics +

Abstract

Approved by the Food and Drug Administration in 2011, the anti‑cytotoxic T‑lymphocyte‑associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of ≥3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated with this agent in routine practice. Toxicity and efficacy of agents in “real world” settings may differ from trials. The present study aimed to evaluate, with respect to toxicity and outcome, all patients treated with ipilimumab to date at the Princess Margaret Hospital (Toronto, Canada). Patients treated with ipilimumab between 2008 and 2013 were identified, and patient characteristics (age, gender, tumour burden, oncogenic mutation status, number of treatments received and toxicities from treatment) were collected. Progression‑free survival (PFS) and overall survival (OS) were calculated from the commencement of ipilimumab treatment. Associations between clinical characteristics and outcome or toxicity were assessed. Between 2008 and 2013, 129 patients with metastatic cutaneous melanoma were treated. Since, during this period, ipilimumab was approved in the second line setting, ipilimumab was delivered in the second or subsequent line in all patients, and 70% did not receive any further anticancer therapy. Immune‑related toxicities were observed, the onset of which varied from 1 to 162 days. The majority resolved within 6 weeks of the final treatment, with the exception of endocrinopathies and bowel related toxicity. The median PFS and OS were 2.83 and 8.44 months, respectively. No pre‑treatment factor independently predicted toxicity. The number of infusions (4 vs. ≤3) and presence of toxicity were significantly associated with superior survival. The onset of toxicity secondary to ipilimumab could occur later than previously reported. Toxicities were manageable, but required long‑term vigilance.

View Figures

View References

1	Canadian Cancer Society: Canadian Cancer Statistics. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=skAccessed. August 01–2014
2	Gedye C, Hogg D, Butler M and Joshua AM: New treatments for metastatic melanoma. CMAJ. 186:754–760. 2014. View Article : Google Scholar : PubMed/NCBI
3	Hodi FS, ODay SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
4	Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
5	Schadendorf D, Robert C, Weber JS, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J Clin Oncol. 33:1889–1894. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tarhini A: Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo). 2013:8575192013.PubMed/NCBI
7	Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
8	Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117. 2014. View Article : Google Scholar : PubMed/NCBI
9	Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts. 32:LBA90082014.
10	Johnson DB, Lovly CM, Flavin M, et al: NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). ASCO Meeting Abstracts. 31:90192013.
11	Zimmerman ZF, Storer B, Godara A, et al: Outcomes and clinical markers associated with benefit from ipilimumab (Ipi) in patients with advanced melanoma: A retrospective single-institution study. ASCO Meeting Abstracts. 31:e200482013.
12	Kelderman S, Heemskerk B, van Tinteren H, et al: Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 63:449–458. 2014.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles